I Squared Capital establishes nLighten, a European edge datacenter platform
8.2.2023 16:43:00 EET | Business Wire | Press release
I Squared Capital, through its ISQ Global Infrastructure Fund III, has established nLighten, an edge datacenter platform dedicated to delivering solutions for both traditional and low-latency use cases. I Squared has committed more than $500 million of equity to support nLighten’s ambition to bring high quality colocation services to underserved cities and regions across Europe. nLighten is part of I Squared Capital’s global datacenter portfolio, including KIO in the Americas and BDx in Asia.
nLighten is led by former senior executives from Equinix, including Harro Beusker, Co-Founder and CEO, and Chad McCarthy, Co-Founder and CTO. Harro has held various leadership roles at Equinix, including SVP of Corporate Development for EMEA, Managing Director Germany and Netherlands and Interim Managing Director France, and Chad was most recently Equinix’s Global Head of Engineering Development and Master Planning. Both were instrumental in the development of Equinix’s business in EMEA as well as key global initiatives like its hyperscale platform, xScale. Other members of the management team include Christian Zipp, former VP of Sales of Germany and Netherlands for Digital Realty and before that Regional VP of Sales in Germany for Equinix, and Martin Essig, former MD of Telecity Germany.
nLighten’s initial focus will be in Germany, where it expects to open ten strategic locations in Berlin, Düsseldorf, Frankfurt, Hamburg, Hannover, Cologne, Leipzig, Munich, Nuremberg, and Stuttgart in the second half of 2023. Through the combination of a distributed nationwide footprint and innovative connectivity partnerships, nLighten intends to offer a latency of 2 to 6 milliseconds to most 5G and last-mile users. The company is also pursuing the deployment of innovative energy solutions, including grid stabilization and the recovery and export of heat to nearby buildings and utility networks.
“With our team of experienced professionals, we are looking to create a step-change in the datacenter industry,” said Harro Beusker, CEO and Co-Founder of nLighten. “We will be close to the customer, bring connectivity ecosystems to regional markets, and actively support the energy transition.”
About nLighten
With its German headquarters in Eschborn, near Frankfurt am Main, nLighten is a digital infrastructure platform and a portfolio company of I Squared Capital. Founded in 2021 by a core team with many years of experience and wide-ranging expertise in the datacenter sector, nLighten intends to build, acquire and operate multiple edge datacenter platforms across Europe. (https://www.nlighten.eu)
nLighten acquired its initial data centers in Germany from EXA Infrastructure, another portfolio company of I Squared Capital.
About I Squared Capital
I Squared Capital is an independent global infrastructure investment manager with over $36 billion in assets under management focusing on energy, utilities, digital infrastructure, environmental infrastructure, transport and social infrastructure in North America, Europe, Latin America and Asia. The firm has offices in Miami, Hong Kong, London, New Delhi, Singapore, Taipei, and Sydney.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207006198/en/
Contact information
Andreas Moon
Partner and Head of Investor Relations
I Squared Capital
andreas.moon@isquaredcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
